The guidelines of the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) suggest that patients with obesity, T2D, and CKD need either glucagon-like peptide 1 receptor analogues (GLP1RA) or sodium-glucose cotransporter-2 inhibitors (SGLT2i). This evidence concerns the gene SLC5A2 and chronic kidney disease.